Sirtris Pharmaceuticals to Present at BioCentury Future Leaders in the Biotech Industry Conference 2006
Posted on: Tuesday, 28 March 2006, 09:01 CST
CAMBRIDGE, Mass., March 28 /PRNewswire/ -- Sirtris Pharmaceuticals, the leading sirtuin therapeutics company, today announced that it will be presenting at the BioCentury Future Leaders in the Biotech Industry Conference in New York. Christoph Westphal, M.D., Ph.D., Chief Executive Officer of Sirtris, will provide an overview of the Company and discuss the Company's strategy for discovering and developing first in class therapeutics that modulate sirtuins, the body's own health-promoting proteins. His presentation will be delivered at 10:30am EST on Thursday, March 30th, 2006.
About Sirtris Pharmaceuticals
Sirtris Pharmaceuticals is a biopharmaceutical company developing and commercializing novel therapeutics that modulate sirtuins, a recently discovered family of enzymes that promotes the body's natural defense against disease. Also known as class III histone deacetylases (HDACs), sirtuins are attractive drug targets for diseases of aging, including metabolic and neurological diseases. Sirtris has built the dominant sirtuin intellectual property estate and know-how, with a comprehensive suite of reagents, proprietary assays, transgenic animal models, and biomarkers.
Sirtris Pharmaceuticals was founded by Rich Aldrich, Richard Pops, Paul Schimmel, David Sinclair and Christoph Westphal, and has raised $45 million in private equity from leading venture capital firms including Polaris Venture Partners, Techno Venture Management, Cardinal Partners, Skyline Ventures, Three Arch Partners, The Wellcome Trust, Novartis Bioventures Fund, Cargill Ventures, Hunt Ventures, and Red Abbey. The company's headquarters are in Cambridge, Massachusetts. For additional information, please visit http://www.sirtrispharma.com/.
Media Contact: Kathryn Morris 845-635-9828
Sirtris Pharmaceuticals
CONTACT: Kathryn Morris of Sirtris Pharmaceuticals, +1-845-635-9828
Web site: http://www.sirtrispharma.com/
Source: PRNewswire
Related Articles
- M/C Venture Partners Names New General Partners and Partner
- Mobile Internet Services Will Dominate The News in 2008, According to M/C Venture Partners' Top-10 Trends To Watch List
- Sirtris Pharmaceuticals Initiates Phase 2a Clinical Trial in Patients With Type 2 Diabetes
- Sirtris Pharmaceuticals, Inc. Announces Initiation of Phase 1b Clinical Trial of SRT501 in MELAS
- Salvatore Tirabassi Joins M/C Venture Partners As Partner
- M/C Venture Partners and Wachovia Capital Partners to Buy National Grid Wireless US for $290 Million
- Sirtris Pharmaceuticals Hires Mike Jirousek As SVP of Research
- New Leaf Venture Partners Announces $12 Million Financing in Tioga Pharmaceuticals
- PlateSpin Secures $7.4 Million Financing Led By Insight Venture Partners
- Chris Rust Named General Partner at U.S. Venture Partners; New GP Contributes Substantial Experience As Entrepreneur and Venture Capitalist
 |
 |
User Comments (0)
RSS Feeds